XTL Biopharmaceuticals Ltd. - American Depositary Shares (XTLB)
XTLB moved a median of +0.02% 30 minutes after news, and +1.85% by the close. How XTLB actually reacts to news — the realized, point-in-time move the market made, measured across 73 labeled events over the last three years with zero look-ahead.
XTLB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 57 |
| 30-min | +0.02% | 51% | 63 |
| 60-min | +0.92% | 56% | 68 |
| to close | +1.85% | 65% | 71 |
| Middle 50% of XTLB reactions | -2.09% to +2.04% |
|---|---|
| Median reaction (30-min) | +0.02% |
| Measured reactions | 73 |
Half of all XTL Biopharmaceuticals Ltd. - American Depositary Shares news events land between -2.09% and +2.04% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when XTLB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to XTLB's baseline. Nothing else.
Recent XTLB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K XTL BIOPHARMACEUTICALS For: Oct 14 | SEC filing · Form 6-K | SEC EDGAR | +0.54% | +2.69% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Aug 05 | SEC filing · Form 6-K | SEC EDGAR | — | +3.98% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Jul 21 | SEC filing · Form 6-K | SEC EDGAR | -4.93% | +2.82% | |
| Form 20-F XTL BIOPHARMACEUTICALS For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.62% | +3.32% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.62% | +3.32% | |
| XTL Completed the Acquisition of Psyga Bio Ltd. | Press release | GlobeNewswire | +0.62% | +3.32% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Jun 29 | SEC filing · Form 6-K | SEC EDGAR | +1.57% | +7.48% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Jun 22 | SEC filing · Form 6-K | SEC EDGAR | +1.17% | +8.56% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: May 22 | SEC filing · Form 6-K | SEC EDGAR | +1.22% | -3.64% | |
| XTL Announces Receipt of Staff Delist Determination from Nasdaq | Press release | GlobeNewswire | +1.22% | -3.64% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: May 15 | SEC filing · Form 6-K | SEC EDGAR | +1.93% | +4.36% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: May 07 | SEC filing · Form 6-K | SEC EDGAR | -2.20% | -16.04% | |
| Form NT 20-F XTL BIOPHARMACEUTICALS For: Dec 31 | SEC filing · Form NT | SEC EDGAR | -2.04% | -7.13% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Apr 29 | SEC filing · Form 6-K | SEC EDGAR | -6.67% | -6.81% | |
| XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies | Press release | GlobeNewswire | -6.67% | -6.81% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Mar 20 | SEC filing · Form 6-K | SEC EDGAR | -1.17% | -2.40% | |
| XTL Biopharmaceuticals Announces ADS Ratio Change | Press release | GlobeNewswire | -1.17% | -2.40% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Mar 10 | SEC filing · Form 6-K | SEC EDGAR | -4.70% | +1.53% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Feb 27 | SEC filing · Form 6-K | SEC EDGAR | +6.47% | +16.75% | |
| XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing | Press release | GlobeNewswire | +6.47% | +16.75% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Feb 24 | SEC filing · Form 6-K | SEC EDGAR | — | +3.13% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Feb 23 | SEC filing · Form 6-K | SEC EDGAR | -8.96% | +4.02% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Feb 17 | SEC filing · Form 6-K | SEC EDGAR | -2.59% | +12.42% | |
| XTL Update on Recent Developments | Press release | GlobeNewswire | — | +0.53% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Jan 28 | SEC filing · Form 6-K | SEC EDGAR | +1.84% | +2.60% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Jan 23 | SEC filing · Form 6-K | SEC EDGAR | -4.57% | -9.22% | |
| XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency | Press release | GlobeNewswire | -4.57% | -9.22% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Jan 13 | SEC filing · Form 6-K | SEC EDGAR | -9.17% | +23.41% | |
| XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership | Press release | GlobeNewswire | -9.17% | +23.41% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Dec 30 | SEC filing · Form 6-K | SEC EDGAR | — | +2.81% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Dec 29 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -4.66% | |
| XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency | Press release | GlobeNewswire | +0.00% | -6.47% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Dec 12 | SEC filing · Form 6-K | SEC EDGAR | +1.12% | -4.77% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Dec 05 | SEC filing · Form 6-K | SEC EDGAR | — | +2.79% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Oct 22 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Jul 28 | SEC filing · Form 6-K | SEC EDGAR | +1.19% | — | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Jul 21 | SEC filing · Form 6-K | SEC EDGAR | — | +3.41% | |
| Form 6-K/A XTL BIOPHARMACEUTICALS For: Jun 18 | SEC filing · Form 6-K | SEC EDGAR | — | -17.35% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Jun 13 | SEC filing · Form 6-K | SEC EDGAR | +1.79% | +8.93% | |
| Form 20-F XTL BIOPHARMACEUTICALS For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +9.09% | +6.99% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Apr 07 | SEC filing · Form 6-K | SEC EDGAR | -1.63% | -8.54% | |
| XTL Names Mr. Noam Band as its New Chief Executive Officer | Press release | GlobeNewswire | -1.63% | -8.54% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Mar 04 | SEC filing · Form 6-K | SEC EDGAR | -11.26% | -9.06% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Feb 03 | SEC filing · Form 6-K | SEC EDGAR | — | -1.76% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Dec 30 | SEC filing · Form 6-K | SEC EDGAR | +0.02% | +9.50% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Nov 19 | SEC filing · Form 6-K | SEC EDGAR | — | +0.00% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Nov 12 | SEC filing · Form 6-K | SEC EDGAR | — | +5.06% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Oct 15 | SEC filing · Form 6-K | SEC EDGAR | +0.45% | -10.76% | |
| Form 6-K XTL BIOPHARMACEUTICALS For: Aug 14 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +1.52% | |
| XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million | Press release | GlobeNewswire | +0.00% | +1.52% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the XTLB section they belong to.
Where else XTLB is measured.
XTLB earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BIOASIS TECHNOLOGIES INC (BIOAF) | 73 | 0.00% | 20% |
| CHARLOTTES WEB HLDGS INC (CWBHF) | 73 | +1.18% | 53% |
| ARRAYIT CORP (ARYC) | 71 | -1.05% | 36% |
| Aeterna Zentaris Inc. (AEZS) | 70 | +0.61% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is XTL Biopharmaceuticals Ltd. - American Depositary Shares's median reaction calculated?
Every labeled XTLB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 73 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of XTLB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does XTLB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.